Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Licenses BRAF Mutation Technology to GlaxoSmithKline

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today said that it has licensed to GlaxoSmithKline non-exclusive rights to its PCR technology and "diagnostic expertise" to assess BRAF gene mutations in human tumor samples.

The BRAF gene encodes B-Raf proto-oncogene serine/threonine-protein kinase, a protein that is involved in cell signaling and cellular growth and differentiation. Mutations of the gene have been associated with the development of certain forms of cancer, particularly melanoma, and GSK is one of multiple drug firms pursuing the development of BRAF inhibitors.

Los Angeles-based Response Genetics said that it will receive certain agreed-to milestone payments, but further financial terms of the agreement were not disclosed.

Kathleen Danenberg, president and CEO of Response Genetics, noted that the firm already provides GSK with genetic testing services to support its drug development programs.

Response Genetics sells its ResponseDX: Colon, ResponseDX: Lung, and ResponseDX: Gastric genetic test panels in the US directly and through an agreement with NeoGenomics Laboratories inked in September 2008. All of the tests are performed at Response Genetics' CLIA-certified lab.

In Tuesday afternoon trade on the Nasdaq, shares of Response Genetics were up 32 percent at $2.83.

The Scan

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.